Immune response
Gene:
SPA17 (official gene symbol)Other symbol:
SPA17CT family:
CT22CT identifier:
CT22Aliases from NCBI:
SP17 , SP17-1Humoral immune response
Antibodies against SPA17 were found in multiple myeloma and esophageal carcinoma patients (Lim et al., 2001 PMID: 11222401; Gupta et al., 2007 PMID: 17230514) and in vasectomized men, as well (Lea et al., 1997 PMID: 9022615).
Cellular immune response
Sp17-specific cytotoxic T lymphocytes (CTLs) were generated from patients with myeloma (Chiriva-Internati et al., 2001 PMID: 11477539) and ovarian carcinoma (Chiriva-Internati et al., 2002 PMID: 12015770). Chiriva-Internati et al., 2003 (PMID: 14566839)have identified a nonapeptide sequence within the Sp17 protein that is predicted to have a high binding affinity for the HLA-A1 molecules. Cultured cytotoxic T lymphocytes specific for sperm protein 17 can eradicate human metastatic ovarian cancer cells in a mouse model (Chiriva-Internati et al., 2008). SPA17 epitopes recognized by T cells have been identified after stimulation of lymphocytes in vitro (Cancer Immunity Peptide Database).
| HLA | HLA Frequency (%) | Peptide | Position | Lymphocyte Stimulation Method |
PMID |
|---|---|---|---|---|---|
| A1 | 26 | ILDSSEEDK | 103-111 | protein | 14566839 |
Induced immune response
There are no published reports that evaluated induced immune responses in patients vaccinated with SPA17.